Concord Biotech

When is the next results date for Concord Biotech?

No Upcoming Board Meetings

Has Concord Biotech declared dividend?

Yes, Concord Biotech Ltd has declared an 875% dividend, amounting to ₹8.75 per share, with an ex-date of June 21, 2024. While the 1-year total return is 33.35%, the recent 6-month return is -10.59%.

Yes, Concord Biotech Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 875%<BR>- Amount per share: 8.75<BR>- Ex-date: Jun-21-2024<BR><BR>Dividend Yield: 0.47%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -10.59%, the dividend return was 0%, resulting in a total return of -10.59%.<BR><BR>For the 1-year period, the price return was 32.75%, the dividend return was 0.60%, leading to a total return of 33.35%.<BR><BR>Over the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>For the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the 5-year period, the price return was 0% and the dividend return was also 0%, resulting in a total return of 0.0%.<BR><BR>Overall, while Concord Biotech has declared a significant dividend, the total returns over various periods show mixed performance, with a notable positive return in the 1-year period but negative returns in the recent 6-month period.

Is Concord Biotech overvalued or undervalued?

As of August 21, 2023, Concord Biotech is considered very expensive and overvalued, with high valuation ratios significantly exceeding its peers, despite a strong 38.84% return over the past year.

As of 21 August 2023, Concord Biotech's valuation grade has moved from does not qualify to very expensive. The company is currently overvalued based on its high valuation ratios, including a PE ratio of 54.06, an EV to EBITDA of 39.12, and a PEG ratio of 2.41. These figures significantly exceed those of its peers, such as Sun Pharmaceutical Industries Ltd. with a PE of 35.25 and Divi's Laboratories Ltd. with an EV to EBITDA of 57.35.<BR><BR>In comparison to its peers, Concord Biotech's financial metrics suggest it is trading at a premium, indicating a lack of justification for its current price. While the company has shown strong returns over the past year, outperforming the Sensex with a 38.84% return compared to the Sensex's 7.53%, the overall valuation still reflects an overvalued status in the current market landscape.

Who are the peers of the Concord Biotech?

Concord Biotech's peers include Pfizer, ERIS Lifescience, Astrazeneca, OneSource Specialty, Alembic Pharma, Neuland Labs, Jubilant Pharma, Natco Pharma, and Sai Life. ERIS Lifescience has the highest 1-year return at 74.62%, while Concord Biotech's return is 7.74%, higher than Natco Pharma's -20.35%.

Peers: The peers of Concord Biotech are Pfizer, ERIS Lifescience, Astrazeneca Phar, OneSource Speci., Alembic Pharma, Neuland Labs., Jubilant Pharmo, Natco Pharma, and Sai Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech, while Good management risk is found at Pfizer, ERIS Lifescience, Astrazeneca Phar, Alembic Pharma, Neuland Labs., and Natco Pharma, and the rest. Below Average management risk is noted for Jubilant Pharmo, while Average management risk is seen at Sai Life. Growth is rated as Excellent for OneSource Speci., Good for Concord Biotech and Natco Pharma, Average for Neuland Labs., and Below Average for Pfizer, ERIS Lifescience, Astrazeneca Phar, Alembic Pharma, and the rest. Capital Structure is Excellent for Pfizer, ERIS Lifescience, Astrazeneca Phar, Alembic Pharma, Neuland Labs., and Natco Pharma, while Below Average is noted for OneSource Speci., and Average for Jubilant Pharmo.<BR><BR>Return Snapshot: The peer with the highest 1-year return is ERIS Lifescience at 74.62%, while the lowest is Natco Pharma at -20.35%. Concord Biotech's 1-year return of 7.74% is higher than Natco Pharma's but lower than ERIS Lifescience's. Additionally, Natco Pharma and Concord Biotech have negative six-month returns.

Who are in the management team of Concord Biotech?

As of March 2023, the management team of Concord Biotech includes Sudhir Jairam Vaid (Chairman & Managing Director), Ankur Vaid (Joint Managing Director & CEO), and several independent and non-executive directors, totaling 13 key members who guide the company's governance and strategy.

As of March 2023, the management team of Concord Biotech includes the following individuals:<BR><BR>1. Sudhir Jairam Vaid - Chairman & Managing Director<BR>2. Ankur Vaid - Joint Managing Director & CEO<BR>3. Ravi Kapoor - Non Executive Director<BR>4. Rajiv Agarwal - Nominee<BR>5. Utpal Sheth - Nominee<BR>6. Amit Varma - Nominee<BR>7. Bharti Khanna - Independent Director<BR>8. Anil Katyal - Independent Director<BR>9. Amitabh Thakore - Independent Director<BR>10. Arvind Agarwal - Independent Director<BR>11. Jayaram Easwaran - Independent Director<BR>12. Mandayam Chakravarthy Sriraman - Independent Director<BR>13. S Prakash - Vice President & Company Secretary<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

What does Concord Biotech do?

Concord Biotech Ltd is a mid-cap pharmaceutical and biotechnology company, originally founded in 1984, with net sales of ₹4,299 Cr and a net profit of ₹1,404 Cr as of March 2025. The company has a market cap of ₹19,274 Cr and key metrics include a P/E ratio of 52.00 and a return on equity of 20.62%.

Overview: <BR>Concord Biotech Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History: <BR>Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited in 1984. The company changed its name to Concord Biotech Limited in 2001, transitioning to a Public Company. The latest quarterly results reported are for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 4,299 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1,404 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 19,274 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 52.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.18 <BR>Return on Equity: 20.62% <BR>Price to Book: 12.14 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Concord Biotech?

The top shareholders of Concord Biotech include Sudhir Vaid, who holds 28.84%, followed by 22 mutual funds with 5.16%, 92 foreign institutional investors with 9.35%, and the Aryaman Jhunjhunwala discretionary trust at 8.03%. Individual investors own a total of 6.94% of the company.

The top shareholders of Concord Biotech include the promoters, who hold the majority of the shares. The promoter with the highest holding is Sudhir Vaid, owning 28.84% of the company. Additionally, there are 22 mutual funds that collectively hold 5.16% of the shares, while 92 foreign institutional investors (FIIs) hold 9.35%. The highest public shareholder is the Aryaman Jhunjhunwala discretionary trust, which holds 8.03%. Individual investors collectively own 6.94% of the company.

How big is Concord Biotech?

As of 24th July, Concord Biotech Ltd has a market capitalization of 20,411.00 Cr, with recent net sales of 1,200.08 Cr and net profit of 371.64 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Concord Biotech Ltd has a market capitalization of 20,411.00 Cr, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,200.08 Cr, while the sum of Net Profit for the same period is 371.64 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 1,526.65 Cr and Total Assets valued at 1,700.71 Cr.

Is Concord Biotech technically bullish or bearish?

As of October 7, 2025, Concord Biotech's trend is mildly bearish due to bearish signals from the MACD and Bollinger Bands, despite some underlying buying pressure indicated by the On-Balance Volume.

As of 7 October 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and Bollinger Bands indicating bearish signals. The daily moving averages also reflect a bearish outlook. However, the On-Balance Volume (OBV) shows bullish strength on both weekly and monthly time frames, suggesting some underlying buying pressure. Overall, the lack of strong bullish indicators and the presence of bearish signals in multiple areas indicate a cautious stance on Concord Biotech.

How has been the historical performance of Concord Biotech?

Concord Biotech has shown consistent growth over the past four years, with net sales increasing from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, and profit after tax rising from 178.57 Cr to 372.96 Cr. However, cash flow management faced challenges, with a decline in operating cash flow and a net cash outflow in the latest fiscal year.

Answer:<BR>The historical performance of Concord Biotech shows a consistent growth trajectory in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Concord Biotech's net sales have increased from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 712.93 Cr to 1,200.09 Cr during the same period. The company's total expenditure, excluding depreciation, also grew from 439.66 Cr in Mar'22 to 693.76 Cr in Mar'25, indicating increased operational costs. Operating profit (PBDIT) saw a significant rise from 296.69 Cr in Mar'22 to 550.78 Cr in Mar'25, showcasing improved profitability. Profit before tax increased from 241.16 Cr to 495.87 Cr, while profit after tax rose from 178.57 Cr to 372.96 Cr, demonstrating effective cost management and revenue generation. The earnings per share (EPS) improved from 16.72 in Mar'22 to 35.53 in Mar'25, reflecting enhanced shareholder value. On the balance sheet, total assets grew from 1,312.79 Cr to 2,034.25 Cr, and total liabilities increased from 1,312.79 Cr to 2,034.25 Cr, indicating a robust growth in the company's financial position. Cash flow from operating activities showed a slight decline from 265.00 Cr in Mar'24 to 244.00 Cr in Mar'25, while net cash outflow was recorded at -14.00 Cr in Mar'25, down from a positive inflow of 11.00 Cr in Mar'24. Overall, Concord Biotech has demonstrated strong growth in sales, profits, and asset base, although cash flow management appears to have faced some challenges in the latest fiscal year.

Are Concord Biotech Ltd latest results good or bad?

Concord Biotech Ltd's latest results show mixed performance: while revenue grew by 12.43% quarter-on-quarter, net profit declined by 15.07% year-on-year, and operating margins fell to 35.64%. Overall, the results indicate underlying operational challenges despite some positive revenue growth.

Concord Biotech Ltd's latest results present a mixed picture. On one hand, the company achieved a revenue growth of 12.43% quarter-on-quarter, reaching ₹277.77 crores, which is a positive sign. Year-on-year, revenue also increased by 13.74%. However, profitability metrics tell a different story. The net profit for the quarter was ₹64.48 crores, reflecting a modest increase of 1.42% compared to the previous quarter but a significant decline of 15.07% year-on-year.<BR><BR>Operating margins have come under pressure, dropping to 35.64% from 40.11% a year earlier, indicating ongoing cost challenges. This margin compression raises concerns about the company's ability to maintain profitability in the face of rising costs. Additionally, the company has underperformed compared to the broader pharmaceutical sector, which has seen positive returns, while Concord Biotech's stock has declined significantly over the past year.<BR><BR>Overall, while there are some positive indicators in terms of revenue growth, the decline in profitability and margins suggests that the results are not entirely favorable, pointing to underlying operational challenges that need to be addressed.

Should I buy, sell or hold Concord Biotech Ltd?

Why is Concord Biotech Ltd falling/rising?

As of 17-Mar, Concord Biotech Ltd's stock price is declining, currently at 1,125.05, reflecting a 2.74% decrease. The stock has underperformed significantly over various timeframes, with a year-to-date decline of 16.38% and negative financial results contributing to its bearish trend.

As of 17-Mar, Concord Biotech Ltd's stock price is falling, currently at 1,125.05, which reflects a decrease of 31.75 or 2.74%. This decline is part of a broader trend, as the stock has underperformed the sector by 3.02% today and has experienced consecutive falls over the last two days, totaling a drop of 4.67% in that period. <BR><BR>The stock's performance over various timeframes also indicates a troubling trajectory, with a year-to-date decline of 16.38% and a significant drop of 29.64% over the past year. In contrast, the Sensex has shown a modest increase of 2.56% over the same one-year period, highlighting the stock's underperformance relative to the market.<BR><BR>Today's trading activity further illustrates the stock's struggles, as it traded below its moving averages across multiple timeframes, indicating a bearish trend. The intraday high of Rs 1181.4 was not sustained, as the stock fell to a low of Rs 1122.85. Additionally, while there has been a rise in investor participation with a 202.44% increase in delivery volume compared to the five-day average, this has not translated into positive price movement.<BR><BR>The company's financial health is also a concern, with negative results reported for the last three consecutive quarters, including a 15.9% decline in profit before tax and a 17.4% drop in profit after tax compared to previous averages. The operating profit has seen a negative growth rate of -0.34% over the last five years, contributing to a perception of poor long-term growth potential.<BR><BR>Overall, the combination of negative financial results, underperformance relative to benchmarks, and a lack of positive momentum in trading has led to the current decline in Concord Biotech Ltd's stock price.

Why is Concord Biotech Ltd falling/rising?

As of 18-Mar, Concord Biotech Ltd's stock price is rising to 1,141.40, reflecting a short-term increase despite a year-to-date decline of 15.17% and ongoing long-term challenges. The stock's recent performance is buoyed by increased investor participation, but concerns remain due to stagnant profit growth and high valuation.

As of 18-Mar, Concord Biotech Ltd's stock price is rising, currently at 1,141.40, reflecting an increase of 11.95 (1.06%). This upward movement follows a trend reversal after two consecutive days of decline. Notably, the stock has outperformed its sector by 0.79% today and reached an intraday high of Rs 1166.15, which is a 3.25% increase.<BR><BR>Despite this short-term rise, the stock has shown poor performance over longer periods, with a year-to-date decline of 15.17% and a significant drop of 31.07% over the past year. The company has faced challenges, including negative results for the last three consecutive quarters, which have contributed to its overall underperformance. Additionally, while the stock is currently experiencing increased investor participation, as evidenced by an 81.1% rise in delivery volume, the long-term outlook remains concerning due to stagnant operating profit growth and a high valuation relative to its return on equity.<BR><BR>In summary, the current rise in Concord Biotech Ltd's stock price is a short-term reaction amidst a backdrop of longer-term challenges and underperformance.

Why is Concord Biotech Ltd falling/rising?

As of 19-Mar, Concord Biotech Ltd's stock price is declining, currently at 1,098.50, reflecting a 3.76% drop. The stock has underperformed significantly, with negative financial results and trading below its moving averages, indicating a bearish trend.

As of 19-Mar, Concord Biotech Ltd's stock price is falling, currently at 1,098.50, which reflects a decrease of 42.9 points or 3.76%. This decline is evident in the stock's performance over various periods, including a 6.44% drop over the past week and an 18.35% decrease year-to-date. Additionally, the stock has underperformed compared to the Sensex, which has only fallen by 2.40% over the same week.<BR><BR>Today's trading activity indicates further weakness, as the stock is close to its 52-week low, just 3.8% above the low of Rs 1056.75. It reached an intraday low of Rs 1095.2, marking a 4.05% decline during the day. The stock is also trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend.<BR><BR>The company's financial performance has been concerning, with negative results reported for the last three consecutive quarters. Operating profit has seen a slight annual decline of 0.34% over the past five years, and both profit before tax and profit after tax have fallen significantly compared to previous quarters. This poor financial outlook, combined with a high price-to-book value ratio of 6.3 and a return on equity of 17.7, suggests that the stock is overvalued relative to its peers.<BR><BR>Overall, the combination of declining stock performance, negative financial results, and underperformance against benchmarks contributes to the downward pressure on Concord Biotech Ltd's stock price.

Why is Concord Biotech Ltd falling/rising?

As of 20-Mar, Concord Biotech Ltd's stock price is declining, currently at 1,092.45, reflecting a significant downward trend and underperformance compared to the Sensex. The company has reported negative financial results for three consecutive quarters, leading to decreased investor interest and a bearish outlook.

As of 20-Mar, Concord Biotech Ltd's stock price is falling, currently at 1,092.45, reflecting a decrease of 8.9 points or 0.81%. The stock has been on a downward trend, having lost 4.29% over the last two days and is down 7.43% over the past week, significantly underperforming the Sensex, which has only decreased by 0.04% in the same period.<BR><BR>The stock is also close to its 52-week low, just 3.27% away from Rs 1,056.75, indicating a lack of upward momentum. Additionally, it has been trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a persistent bearish trend. Investor participation has decreased sharply, with delivery volume dropping by 75.7% compared to the 5-day average, which further indicates waning interest in the stock.<BR><BR>Financially, the company has reported negative results for the last three consecutive quarters, with operating profit declining at an annual rate of -0.34% over the past five years. Key metrics such as profit before tax and profit after tax have also fallen significantly, by 15.9% and 17.4% respectively, compared to previous quarterly averages. This poor performance is compounded by a return on equity (ROE) of 17.7, which is considered expensive given its price-to-book value of 6.3, despite the stock trading at a discount compared to its peers.<BR><BR>Overall, the combination of declining stock performance, negative financial results, and reduced investor interest are contributing to the falling price of Concord Biotech Ltd.

Why is Concord Biotech Ltd falling/rising?

As of 23-Mar, Concord Biotech Ltd's stock price is at Rs. 1,018.00, reflecting a 6.81% decline and a total drop of 10.81% over the past three days. The stock has underperformed significantly, with a year-to-date decline of 24.34% and a 39.69% drop over the past year, driven by negative financial results and decreased investor interest.

As of 23-Mar, Concord Biotech Ltd's stock price is falling, currently at Rs. 1,018.00, which represents a decline of Rs. 74.45 or 6.81%. This drop is part of a broader trend, as the stock has been losing value for the past three days, accumulating a total decline of 10.81% during this period. Additionally, the stock has reached a new 52-week low today.<BR><BR>The stock's performance has been notably poor over various time frames, with a year-to-date decline of 24.34% and a staggering 39.69% drop over the past year. In comparison to the benchmark Sensex, which has decreased by 5.47% over the same period, Concord Biotech's performance is significantly worse. The stock has also underperformed its sector, with a performance today that lagged behind by 3.24%.<BR><BR>Several factors contribute to this decline. The company has reported negative results for the last three consecutive quarters, with key financial metrics such as profit before tax and profit after tax showing significant declines compared to previous averages. Furthermore, the company's operating profit has experienced a negative growth rate of -0.34% over the last five years, indicating poor long-term growth prospects.<BR><BR>Investor participation has also decreased, with delivery volume falling by 22.07% against the five-day average, suggesting waning interest among investors. The stock is trading below its moving averages across multiple time frames, indicating a bearish trend. Overall, the combination of poor financial performance, declining investor interest, and broader market conditions in the pharmaceuticals and drugs sector, which has fallen by 3.58%, has led to the current decline in Concord Biotech Ltd's stock price.

Why is Concord Biotech Ltd falling/rising?

As of 24-Mar, Concord Biotech Ltd's stock price is rising, indicating a potential short-term recovery after a decline, but it has underperformed over the past year with a return of -37.28%. Investor interest is waning, and the stock is trading below key moving averages, suggesting a bearish trend and a perception of it as a strong sell.

As of 24-Mar, Concord Biotech Ltd's stock price is currently rising, with a change of 3.95 (0.38%) to a current price of 1,037.75. This increase follows a trend reversal after three consecutive days of decline, indicating a potential short-term recovery. The stock reached an intraday high of Rs 1,056.25, reflecting a 2.17% increase during the trading day.<BR><BR>However, despite this recent uptick, the stock has been underperforming in the longer term. Over the past year, it has generated a return of -37.28%, significantly worse than the BSE500 index, which has only declined by 5.02%. Additionally, the stock is currently trading close to its 52-week low, just 1.9% away from Rs 1,018.<BR><BR>Investor participation has also been declining, with delivery volume falling by 57.35% compared to the 5-day average, suggesting reduced interest from investors. Furthermore, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>The company's financial performance has been concerning, with negative results reported for the last three consecutive quarters, including a -15.9% decline in profit before tax compared to the previous four-quarter average. This poor performance, combined with a high price-to-book value ratio and low operating profit growth over the past five years, contributes to a perception of the stock as a strong sell despite the recent price increase.

Why is Concord Biotech Ltd falling/rising?

As of 25-Mar, Concord Biotech Ltd's stock price is slightly rising at 1,037.80, but it has experienced significant declines over various periods, including a 22.87% drop year-to-date and a 38.44% decrease over the past year, indicating a negative overall trend.

As of 25-Mar, Concord Biotech Ltd's stock price is experiencing a slight rise, currently at 1,037.80, with a change of 0.05 (0.00%). However, this minor increase comes against a backdrop of significant declines in the stock's performance over various periods. Over the past week, the stock has fallen by 9.08%, and it has decreased by 14.85% over the last month. Year-to-date, the stock is down 22.87%, and it has seen a substantial decline of 38.44% over the past year.<BR><BR>Despite the recent two-day gain of 0.39%, the stock is still trading below all its moving averages, indicating a general downtrend. Additionally, the stock is close to its 52-week low, just 1.91% away from Rs 1,018. The performance today has underperformed the sector by 1.89%, and there has been a notable decrease in investor participation, with delivery volume falling by 9.09% compared to the 5-day average.<BR><BR>The company's financial health also raises concerns, as it has reported negative results for the last three consecutive quarters, with significant declines in both profit before tax and profit after tax compared to previous averages. Furthermore, the long-term growth outlook appears poor, with an annual operating profit growth rate of -0.34% over the last five years. <BR><BR>In summary, while there has been a slight uptick in the stock price recently, the overall trend remains negative due to poor financial performance, declining investor interest, and significant losses over various time frames.

Which are the latest news on Concord Biotech?